Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03429049 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain
A Phase 3 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
NCT03429049 is a Phase 3 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 332 participants.
The verdict
NCT03429049, a Phase 3 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, double-blind, placebo-controlled, single injection, 52-week study to evaluate the analgesic efficacy and safety of a single intra-articular (IA) CNTX-4975-05 (capsaicin), compared to IA placebo, in subjects with chronic, moderate-to-severe osteoarthritis (OA) knee pain.
Interventions
- DRUG Placebo
- DRUG CNTX-4975-05
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2019-11-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03429049
The ClinicalTrials.gov registry entry for NCT03429049 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03429049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03429049 about?
NCT03429049 is a clinical study titled "A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain". This is a phase 3, randomized, double-blind, placebo-controlled, single injection, 52-week study to evaluate the analgesic efficacy and safety of a single intra-articular (IA) CNTX-4975-05 (capsaicin), compared to IA placebo, in subjects with chronic, moderate-to-severe osteoarthritis (OA) knee pain...
What is the current status of trial NCT03429049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2018-01-24. Estimated completion is 2019-11-22.
What interventions are being tested in trial NCT03429049?
The interventions under investigation include: Placebo (DRUG), CNTX-4975-05 (DRUG).
Who is sponsoring clinical trial NCT03429049?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.